Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined...
32 insider purchases on record · latest filing 2024-09-12.
Insiders have also filed 58 sale transactions at SYRS.